ScoreWhy is BridgeBio Pharma, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Operating profit has grown by an annual rate -1.19% of over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.52
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 62.73%, its profits have fallen by -41.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is BridgeBio Pharma, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
BridgeBio Pharma, Inc.
62.73%
3.05
48.13%
S&P 500
22.24%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
127.44%
EBIT Growth (5y)
-1.19%
EBIT to Interest (avg)
-8.52
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.10
Sales to Capital Employed (avg)
0.32
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-6.68
EV to EBIT
-32.03
EV to EBITDA
-32.38
EV to Capital Employed
319.88
EV to Sales
32.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-998.72%
ROE (Latest)
Negative BV
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend21What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -443.95 MM
NET PROFIT(HY)
Higher at USD -356.56 MM
CASH AND EQV(HY)
Highest at USD 1,528.77 MM
NET SALES(Q)
Highest at USD 194.51 MM
OPERATING PROFIT MARGIN(Q)
Highest at -53.86 %
EPS(Q)
Highest at USD -0.84
-4What is not working for the Company
INTEREST(HY)
At USD 103.13 MM has Grown at 43.31%
Here's what is working for BridgeBio Pharma, Inc.
Operating Cash Flow
Highest at USD -443.95 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 194.51 MM has Grown at 54.97%
over average net sales of the previous four periods of USD 125.52 MMMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Net Profit
Higher at USD -356.56 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Net Sales
Highest at USD 194.51 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit Margin
Highest at -53.86 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
EPS
Highest at USD -0.84
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 1,528.77 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Here's what is not working for BridgeBio Pharma, Inc.
Interest
At USD 103.13 MM has Grown at 43.31%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
